Literature DB >> 17502329

Effect of drug combinations on admission for recurrent myocardial infarction.

Menno E van der Elst1, Marcel L Bouvy, Cornelis J de Blaey, Anthonius de Boer.   

Abstract

OBJECTIVE: To determine the effect of the number of different drugs with adherence to medication of at least 70% on recurrent admission for myocardial infarction (MI) in patients with a history of MI.
DESIGN: Nested case-control study in a dynamic cohort.
SETTING: PHARMO database that contains pharmacy dispensing records and hospital discharge records of 350,000 Dutch citizens.
SUBJECTS: All patients admitted to hospital for first MI (ICD-9 410) from 1991 to 2000 with at least a 30-day survival after admission. Cases were admitted for recurrent MI and were matched for age, sex, and year of admission with controls who did not have a recurrent MI. MAIN OUTCOME MEASURE(S): Odds ratio with 95% CI for admission for recurrent MI. Exposure was the number of preventive drugs (antiplatelet agents, statins and beta blockers or ACE inhibitors) used for at least 70% of the time.
RESULTS: 389 cases were matched with 2344 controls. The use of one drug was associated with a 6% odds reduction (95% CI 30% reduction to 28% increase) for admission for recurrent MI. The use of two or three drugs was associated with reductions of 26% and 41% (47% reduction to 3% increase and 6% to 63% reduction, respectively). Addition of one drug caused a 16% reduction (4% to 26%).
CONCLUSIONS: Multiple drug treatment decreases admissions for recurrent MI in patients with a history of MI. Every addition of a drug, regardless of drug class, reduces the risk even further. These results support the treatment strategies as applied in daily practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502329      PMCID: PMC2000957          DOI: 10.1136/hrt.2006.098053

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

Authors:  S C Smith; S N Blair; R O Bonow; L M Brass; M D Cerqueira; K Dracup; V Fuster; A Gotto; S M Grundy; N H Miller; A Jacobs; D Jones; R M Krauss; L Mosca; I Ockene; R C Pasternak; T Pearson; M A Pfeffer; R D Starke; K A Taubert
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

Authors:  H J Dargie
Journal:  Lancet       Date:  2001-05-05       Impact factor: 79.321

3.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

Authors:  S S Anand; S Yusuf
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction.

Authors:  P Smith; H Arnesen; M Abdelnoor
Journal:  Arch Intern Med       Date:  1992-05

5.  Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.

Authors:  G R Dagenais; S Yusuf; M G Bourassa; Q Yi; J Bosch; E M Lonn; S Kouz; J Grover
Journal:  Circulation       Date:  2001-07-31       Impact factor: 29.690

6.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

7.  Comparison of different methods to estimate prevalence of drug use by using pharmacy records.

Authors:  A K Mantel-Teeuwisse; O H Klungel; W M Verschuren; A Porsius; A de Boer
Journal:  J Clin Epidemiol       Date:  2001-11       Impact factor: 6.437

8.  Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study.

Authors:  Anke Hilse Maitland-van der Zee; Olaf H Klungel; Bruno H Ch Stricker; Deirdre A M van der Kuip; Jacqueline C M Witteman; Albert Hofman; Hubertus G M Leufkens; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2003-04

9.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  5 in total

1.  Case definitions for acute myocardial infarction in administrative databases and their impact on in-hospital mortality rates.

Authors:  Amy Metcalfe; Annabelle Neudam; Samantha Forde; Mingfu Liu; Saskia Drosler; Hude Quan; Nathalie Jetté
Journal:  Health Serv Res       Date:  2012-06-28       Impact factor: 3.402

2.  Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year.

Authors:  Saba Al-Khadra; Christa Meisinger; Ute Amann; Rolf Holle; Bernhard Kuch; Hildegard Seidl; Inge Kirchberger
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

3.  Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction.

Authors:  Gillian E Hanley; Steve Morgan; Robert J Reid
Journal:  J Gen Intern Med       Date:  2011-07-13       Impact factor: 5.128

4.  Optimal medical therapy for secondary prevention after an acute coronary syndrome: 18-month follow-up results at a tertiary teaching hospital in South Korea.

Authors:  Hee Ja Byeon; Young-Mo Yang; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2016-02-12       Impact factor: 2.423

5.  Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis.

Authors:  Tian-Tian Ma; Ian C K Wong; Kenneth K C Man; Yang Chen; Thomas Crake; Muhiddin A Ozkor; Ling-Qing Ding; Zi-Xuan Wang; Lin Zhang; Li Wei
Journal:  PLoS One       Date:  2019-01-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.